Back to results
US 8,618,158 B2Granted
Therapeutic agents
AssigneeCancer Research Technology Limited
InventorsBernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
Life of this patent
Estimating the term…
Abstract
A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
Claims19
A compound of Formula I, or Formula II, or a pharmaceutically acceptable salt thereof,
- wherein in both formulae I and II:
- X is selected from O or S;
- R1 is selected from substituted or unsubstituted aryl, and substituted or unsubstituted aralkyl;
- R2 is selected from:
- (i) hydroxy-2,2-dimethylpropyl, hydroxy-2,2-cyclopropylpropyl, 2-hydroxymethyl allyl, and a succinic acid derivative,
- (ii) hydroxycyclooctyl, hydroxymethylcyclohexylmethylene, and hydroxycyclohexyl, and
- (iii) hydroxymethylbenzyl;
- R3 is selected from substituted or unsubstituted aryl, and substituted or unsubstituted aralkyl and
- R4-R7 represents groups R4, R5, R6 and R7 which are independently selected from hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted alkoxy, trifluoromethyl, amino, nitro, carboxyl, carbonyl, methylsulfone, trifluoromethylsulfone, cyano and substituted or unsubstituted sulfonamide.
6 more elements
Dependencies are inferred from the claim text.